DCM
EVLO

DAFNA Capital Management’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

DAFNA Capital Management’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-536
Closed -$44K – 87
2019
Q4 		$44K Sell
536
-464
-46% -$51.9K 0.02% 81
2019
Q3 		$122K Buy
+1,000
New +$137K 0.05% 85

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

DAFNA Capital Management's EVLO Position: Q1 2020 in Review

DAFNA Capital Management sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q1 2020, closing a stake of 536 shares — an estimated $44K sold.

DAFNA Capital Management first reported a position in EVLO in Q3 2019 and held it in 2 quarters. The position peaked at $122K in Q3 2019. 42 funds tracked by Wall St. Rank hold EVLO as of Q1 2020.

  • DAFNA Capital Management reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • DAFNA Capital Management sold 536 Evelo Biosciences, Inc. Common Stock shares in Q1 2020, an estimated $44K.
  • DAFNA Capital Management first reported a position in Evelo Biosciences, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • DAFNA Capital Management's Evelo Biosciences, Inc. Common Stock position peaked at $122K in Q3 2019.
  • 42 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q1 2020.

Based on DAFNA Capital Management's 13F filing for Q1 2020, filed 15 May 2020.